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Strongyloides (S.) stercoralis and Human T-Lymphotropic Virus 1 (HTLV-1) share some
endemic regions such as Japan, Jamaica, and South America and are mostly diagnosed
elsewhere in immigrants from endemic areas. This co-infection has not been documented
in Argentina although both pathogens are endemic in the Northwest. We present
a case of S. stercoralis and HTLV-1 co-infection with an initial presentation due to
gastrointestinal symptoms which presented neither eosinophilia nor the presence of
larvae in stool samples in a non-endemic area for these infections. A young Peruvian
woman living in Buenos Aires attended several emergency rooms and finally ended up
admitted in a gastroenterology ward due to incoercible vomiting, diarrhea, abdominal
pain, fever, and weight loss. Gastrointestinal symptoms started 3 months before she
returned to Argentina from a trip to Peru. She presented malnutrition and abdominal
distension parameters. HIV-1 and other immunodeficiencies were discarded. The
serial coproparasitological test was negative. Computed tomography showed diffuse
thickening of duodenal and jejunal walls. At the beginning, vasculitis was suspected
and corticosteroid therapy was initiated. The patient worsened rapidly. Skin, new enteral
biopsies, and a new set of coproparasitological samples revealed S. stercoralis. Then,
HTLV-1 was suspected and infection was confirmed. Ivermectin and albendazole were
administrated, until the stool sample remained negative for 2 weeks. Larvae were
not observed in fresh stool, Ritchie method, and agar culture 1 week post-treatment.
Although she required initial support with parenteral nutrition due to oral intolerance
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she slowly progressed favorably. It has been highly recommended to include a rapid
and sensitive PCR strategy in the algorithm to confirm Strongyloides infection, which
has demonstrated to improve early diagnosis in patients at-risk of disseminated
strongyloidiasis.
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INTRODUCTION
The soil-transmitted nematode Strongyloides stercoralis (S.) is
estimated to infect at least 30–100 million people. The prevalence
has been increasing, mainly in Southern, Eastern, and central
Europe, the Caribbean, Southeast Asia, Latin America, and
sub-Saharan Africa (Buonfrate et al., 2015). The filariform
larvae, which inhabit the soil, usually infect humans via skin
penetration. This parasite is the only helminth able to complete
its life cycle inside a single host and some larvae reinfect the host
through the intestinal mucosa or perianal skin, using a process
called autoinfection. The majority of patients develop a chronic,
asymptomatic, or mildly symptomatic infection. Auto-infection
is responsible for chronic infections with eosinophilia being
sometimes the only laboratory finding, while larvae excretion
fluctuates at very low levels (Concha et al., 2005). However,
when auto-infection occurs, the development of disseminated
strongyloidiasis is possible, especially in immunocompromised
hosts like patients treated with corticosteroids, cancer patients
and persons infected with human T-lymphotropic virus
(HTLV-1) (Ramanathan and Nutman, 2008). In these cases,
hyperinfection, characterized by gastrointestinal and pulmonary
hemorrhage, and secondary bacterial infections can occur
(Keiser and Nutman, 2004).
HTLV-1 is an oncoretrovirus that infects ∼10 million
individuals with clusters of high endemicity in certain geographic
areas and ethnic groups, in particular in southwestern Japan,
sub-Saharan Africa, South America, the Caribbean basin and
localized areas in Iran and Australo-Melanesia (Gessain and
Cassar, 2012). There are three possible transmission routes
for HTLV-1: sexual transmission, mother to child transmission
via breast milk, and exposure to contaminated blood. This
retrovirus causes an aggressive malignancy known as adult
T-cell leukemia/lymphoma (ATLL) and a progressive chronic
inflammatory neurological disease named HTLV-1 associated
myelopathy/tropical spastic paraparesis (HAM/TSP) (Barmak
et al., 2003; Proietti et al., 2005). Adult T-cell leukemia was first
identified in Japan by Takatsuki and colleagues in 1977, where a
high incidence in the southwest region was observed (Takatsuki
et al., 1997).
S. stercoralis and HTLV-1 share some endemic regions such
as Japan, Jamaica, and South America and are mostly diagnosed
elsewhere in immigrants from endemic areas (Robinson et al.,
1994; Atsushi, 1995; Gotuzzo et al., 1999; Chieffi et al., 2000).
HTLV-1 infected carriers seem to have an increased risk
of acquiring strongyloidiasis indicating a possible subclinical
immunodeficiency. This retrovirus also predisposes patients to
recurrent and severe infection with S. stercoralis (Carvalho and
Da Fonseca Porto, 2004). The host defense against helminths
may involve both type 1 and 2 immune responses, even
though IL-4, IL-13, IgE mast cells, and eosinophils play an
important role in the elimination of these parasites. Although,
IL-4 and IL-10 produced by Th2 cells have the ability to down-
regulate Th1 cells in HTLV-1/S. stercoralis co-infected patients,
the virus induces a Th1 profile. Hence, IFN-γ can down-
regulate Th2 cells with a diminished antiparasitic response that
induces an increased risk of recurrent and severe forms of
strongyloidiasis with poor response to treatment (Porto et al.,
2001; Carvalho and Da Fonseca Porto, 2004). Furthermore,
administration of immunosuppressive or corticosteroid therapies
in patients with this co-infection may trigger potentially fatal
dissemination (Fardet et al., 2006). Regarding diagnosis, it has
been highly recommended to include a rapid and sensitive
technique in the algorithm to confirm Strongyloides infection
after the first negative result obtained from the fresh stool sample
(e.g., screening before transplantation, initiation of steroid,
immunosuppression status) when this parasitosis is suspected
(Dacal et al., 2017). In Argentina, a very low cost and sensible
PCR has been recently designed, which has demonstrated to
improve early diagnosis in patients at-risk of severe infections
(Repetto et al., 2016). Administration of ivermectin for 1 or 2 days
is the treatment of choice for chronic, asymptomatic infection.
For hyperinfection syndrome and disseminated infections,
ivermectin is the drug of choice with albendazole as a second-
line therapy, until complete eradication of the parasite is achieved
(Gann et al., 1994; Mejia and Nutman, 2012).
CASE REPORT
Ethics Statement
The patient agreed and provided written informed consent for
publication of this case report and any accompanying images.
Due to the observational nature of this case report, no formal
ethics approval was required.
A 25-year-old Peruvian woman living in Buenos Aires,
Argentina attended several emergency rooms and finally ended
up admitted in a gastroenterology ward of the University
Clinical Hospital “José de San Martín,” in March 2016 due to
incoercible vomiting, diarrhea, abdominal pain, fever, weight
loss (>16 kg), and decreased visual acuity in the right eye.
The patient reported that gastrointestinal symptoms had started
3 months before (December 2015) when she returned to
Argentina from a trip to Peru. She presented malnutrition
and abdominal distension parameters. Her admission laboratory
values revealed neutrophilia (26,600/mm3), an increase in
platelets (625,000/mm3), and decreased creatinine (0.44 mg/dL),
sodium (111mmol/l), potassium 5,1 mmol/l, chloride 75 mmol/l,
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and albumina (1.8 g/dL) values. Other values were normal
and the serial coproparasitological test was negative. An inter-
consultation with the ophthalmology ward was requested. HIV-1
and other immunodeficiencies were discarded. The result of a
computed tomography showed diffuse thickening of duodenal
and jejunal walls. A push enteroscopy and videocolonoscopy
showed signs of severe duodenal and jejunal atrophy with
multiple petechial lesions (Figure 1A;Video S1). Then, vasculitis
was suspected and corticosteroid therapy was initiated. The
patient worsened rapidly. Subsequently, urine and blood cultures
detected Escherichia coli and Klebsiella pneumonia, respectively.
Endophthalmitis was also diagnosed. Therefore, antibiotic
treatment was indicated and slight improvement was observed.
Nevertheless, the patient presented fever (38◦C), abdominal pain,
diarrhea stools with mucus and abdominal wall bleeding and
petechiae (Figure 1B). Skin, new enteral biopsies (Figures 1C,D)
and a set of coproparasitological (fresh stool and Ritchie method)
samples revealed S. stercoralis infection. No other pathologies
were found by imaging, blood, and CSF examination. Ivermectin
was administrated but poor response to treatment was observed.
Finally, an interdisciplinary athenaeum was organized with
referents of parasitology and virology from the University of
Buenos Aires.
HTLV-1 was suspected and by April 2016, anti-HTLV-1
antibodies in plasma by ELISA (HTLV I&II Ab, ULTRA version,
Dia.Pro) were detected. For HTLV-1 molecular confirmation
and proviral load (PVL), DNA was extracted from peripheral
blood mononuclear cells (PBMCs) by column extraction (AND
PuriPrep-S kit, Highway R©, Inbio, Argentina) and analyzed by
an “in-house” nested-polymerase chain reaction (n-PCR) and by
real-time SYBR Green PCR (qPCR) respectively, as described
previously (Tuke et al., 1992; Cánepa et al., 2015). HTLV-1 pol
and tax regions were detected and PVL determined a total of
four copies of HTLV-1/100 PBMC. After HTLV-1 detection,
diagnosis was performed on her parents and they were also
confirmedHTLV-1 seropositive, somother-to-child transmission
was suspected. Antiparasitic treatment, including ivermectin and
albendazole were administrated, until the stool sample remained
negative for 2 weeks. Larvae were not observed by fresh stool,
Ritchie method, and agar culture 1 week post-treatment. She
required initial support with parenteral nutrition due to oral
intolerance.
DISCUSSION
S. stercoralis and HTLV-1 share some endemic regions
particularly in South America and are mostly diagnosed
elsewhere in immigrants from endemic areas (Carvalho and Da
Fonseca Porto, 2004; Buonfrate et al., 2015). Eventhough, in
Argentina, where both pathogens are endemic in the Northwest
FIGURE 1 | Petechial lesions and Strongyloides stercoralis larvae detection: (A) A push enteroscopy showing signs of severe duodenal and jejunal atrophy mucosa
with multiple petechial lesions. (B) Abdominal skin rash and petechiae of disseminated Strongyloides. (C) Strongyloides larvae in skin. (D) Strongyloides larvae in
duodenum.
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region, this co-infection has not been documented yet (Biglione
et al., 2005; Repetto et al., 2016).
S. stercoralis patients with HTLV-1 co-infection have a
modified immunological response against parasite antigens and
this has clinical implications for strongyloidiasis. The high
production of IFN-γ observed in co-infected patients induced
by a Th1 profile results in a failure of activation of eosinophils
and reduction of their numbers. This decreases the defense
mechanisms against helminthes leading to an increased risk
of severe forms of strongyloidiasis without eosinophilia (Porto
et al., 2001) In this context, it has been hypothesized that
dissemination of Strongyloides infection could occur due to an
increase in the number of regulatory T cell (Montes et al.,
2009). Otherwise, it has been observed that in this coinfection,
the levels of sIL-2R are higher than those observed in patients
with HTLV-1, and that anthelmintic treatment decreased them.
Consequently, S. stercoralis infection plays a key role in the
immunomodulation of HTLV-1 infection and that may be a
cofactor in the development of ATLL, as reported elsewhere
(Yamaguchi et al., 1987; Salles et al., 2013).
This patient had an initial presentation with gastrointestinal
symptoms, normal values of eosinophils, and without detectable
larvae in different stool samples. This led to symptomatic
treatment without suspicion of infection in several medical
wards. Moreover, and based on a first diagnosis of vasculitis when
she was admitted in the gastroenterology ward, corticosteroids
were administrated resulting in a severe systemic strongyloidiasis
which was diagnosed by detecting larvae in different organs.
Immediately, corticosteroids were suspended and ivermectin
was administrated but due to a poor response to treatment,
HTLV-1 was suspected and confirmed by serological and
molecular techniques. The PVL was low, similar to that of
asymptomatic HTLV-1 individuals, and the patient had no
symptoms associated to this retrovirus. This data indicates that
low PVLs can induce a Th1 profile in asymptomatic carriers
sufficiently enough to have an increased risk of developing
disseminated strongyloidiasis (Porto et al., 2001). When HTLV-
1 infection was confirmed, albendazole was also suggested
and the patient showed a slow but favorable evolution due
to the improvement in the treatment which was strictly
monitored.
This case highlights the fact that all cases of parasitosis
suspicion even without eosinophilia, or presence of larvae in
stool samples, S. stercoralis should be routinely looked for by
a very sensitive technique, especially in HTLV-1 individuals
and patients who travel to and from endemic areas. It has
been demonstrated that early and effective treatment for
strongyloidiasis in HTLV-1 positive patients is important to
prevent recurrent and disseminated strongyloidiasis (Salles et al.,
2013). Regarding this, the use of a sensitive, economical and fast
PCR technique for the confirmation of S. stercoralis infection, at
the onset of the symptoms as proposed by Repetto et al., could
have improved the early diagnosis in a patient at-risk of severe
hyperinfection. This technique should also be performed for
monitoring the treatment, considering it has been documented
that IgG antibody levels decline within 6 months of successful
treatment (Mejia and Nutman, 2012).
Another key factor to keep in mind is the epidemiological
characteristic of these infections. Even though, the young
woman was born and traveled to Peru, an endemic area for
both pathogens, these infections were not initially suspected at
different hospitals in a non-endemic region. This is frequent
for HTLV-1 infection, in Argentina and other countries, where
HTLV remains a “hidden” infection because this retrovirus
circulates with a very low prevalence with the exception of some
restricted regions and/or has not been included in a Health
National Programme for epidemiological surveillance yet (Eirin
et al., 2010). In this case, as her parents were from Peru and were
alsoHTLV-1 positive, themost probable hypothesis is that she got
HTLV-1 infection by vertical transmission and that she acquired
Strongyloides in her last trip to Peru.
This case report is a useful reminder to clinicians that
S. stercoralis as well as HTLV-1 should be considered in
immigrants from endemic areas. Special attention must be
given in this co-infection due to the contraindication of
immunosuppressive or corticosteroid therapies and the decrease
in the efficacy of anti-helmintic drugs (Satoh et al., 2002;
Ramanathan and Nutman, 2008; Roxby et al., 2009). This data
highlights the challenge in continuous clinical monitoring and
reaching a timely and accurate diagnosis to positively impact on
life expectancy.
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